Crystal J Hessman1, Emily J Bubbers2, Kevin G Billingsley3, Daniel O Herzig3, Melissa H Wong4. 1. Department of Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L223, Portland, OR 97239, USA. Electronic address: hessmanc@ohsu.edu. 2. Department of Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L223, Portland, OR 97239, USA. 3. Department of Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L223, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. 4. Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Abstract
BACKGROUND: Colorectal cancer (CRC) progression is mediated by cancer stem cells (CSCs). We sought to determine if the expression of the CSC marker aldehyde dehydrogenase 1 (ALDH1) in CRC tumors varies by American Joint Committee on Cancer stage or correlates to clinical outcomes. METHODS: Primary and metastatic CRC samples from 96 patients were immunostained with antibodies to ALDH1 and imaged to evaluate marker expression. The percentage of ALDH1(+) cells was correlated to clinical outcomes. RESULTS: ALDH1 was overexpressed in CRC tumors compared with nonneoplastic tissue. Marker expression was highest in nonmetastatic tumors. The loss of expression was associated with advanced stage and metastatic disease. No significant correlation was found between ALDH1 expression and metastasis, recurrence, or survival. CONCLUSIONS: ALDH1 was highly expressed in nonmetastatic CRC, but expression was lost with advancing stage. ALDH1 could be an effective therapeutic target in early CRC but not late-stage disease. No correlation was found between ALDH1 and disease prognosis. Published by Elsevier Inc.
BACKGROUND:Colorectal cancer (CRC) progression is mediated by cancer stem cells (CSCs). We sought to determine if the expression of the CSC marker aldehyde dehydrogenase 1 (ALDH1) in CRC tumors varies by American Joint Committee on Cancer stage or correlates to clinical outcomes. METHODS: Primary and metastatic CRC samples from 96 patients were immunostained with antibodies to ALDH1 and imaged to evaluate marker expression. The percentage of ALDH1(+) cells was correlated to clinical outcomes. RESULTS:ALDH1 was overexpressed in CRC tumors compared with nonneoplastic tissue. Marker expression was highest in nonmetastatic tumors. The loss of expression was associated with advanced stage and metastatic disease. No significant correlation was found between ALDH1 expression and metastasis, recurrence, or survival. CONCLUSIONS:ALDH1 was highly expressed in nonmetastatic CRC, but expression was lost with advancing stage. ALDH1 could be an effective therapeutic target in early CRC but not late-stage disease. No correlation was found between ALDH1 and disease prognosis. Published by Elsevier Inc.
Authors: Jan S Moreb; Deniz Ucar; Shuhong Han; John K Amory; Alex S Goldstein; Blanca Ostmark; Lung-Ji Chang Journal: Chem Biol Interact Date: 2011-11-03 Impact factor: 5.192
Authors: Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman Journal: Cancer Res Date: 2009-03-31 Impact factor: 12.701
Authors: Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke Journal: Proc Natl Acad Sci U S A Date: 2007-06-04 Impact factor: 11.205
Authors: Eric C Anderson; Crystal Hessman; Trevor G Levin; Marcus M Monroe; Melissa H Wong Journal: Cancers (Basel) Date: 2011-01-01 Impact factor: 6.639
Authors: Christoph Kahlert; Frank Bergmann; Janine Beck; Thilo Welsch; Carolin Mogler; Esther Herpel; Shamik Dutta; Thomas Niemietz; Moritz Koch; Jürgen Weitz Journal: BMC Cancer Date: 2011-06-27 Impact factor: 4.430
Authors: Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini Journal: Genome Biol Date: 2006-10-31 Impact factor: 13.583
Authors: Salem Y Mohamed; Randa Mohamed Kaf; Mona Mostafa Ahmed; Amira Elwan; Hassan R Ashour; Amr Ibrahim Journal: J Gastrointest Cancer Date: 2019-12